Cogent Biosciences (COGT) Guggenheim SMID Cap Biotech Conference summary

Pipeline and clinical development

• Lead asset bezuclastinib is in three pivotal studies, with readouts expected in 2025: SUMMIT (non-advanced systemic mastocytosis) in July, APEX (advanced systemic mastocytosis) in the second half, and PEAK (GIST in combination with sunitinib) near year-end.

• A new FGFR2 selective inhibitor, CGT4859, has entered phase I trials, expanding the pipeline.

• Enrollment for SUMMIT Part 2 exceeded targets, with 179 patients enrolled in 10 months, driven by strong investigator and patient interest following promising early data.

Differentiation and clinical profile of bezuclastinib

• Bezuclastinib is highly selective for mutant KIT, sparing other kinases and minimizing off-target effects.

• Unlike competitors, it does not penetrate CNS tissue, reducing risk of cognitive side effects.

• Phase I data showed rapid and deep symptom improvement, with a 56% reduction in total symptom score at 24 weeks and nearly 90% of patients achieving at least 50% improvement within a year.

• Safety profile is favorable, with reversible, asymptomatic transaminase elevations and no evidence of true liver toxicity.

Market opportunity and competitive landscape

• Non-advanced systemic mastocytosis market is significant, with first-year sales of $500 million for the current competitor and a total addressable market estimated at $4 billion.

• ASM represents about 10% of the mastocytosis market, or $300–$400 million.

• Bezuclastinib may offer improved symptomatic control and safety compared to avapritinib, especially for patients with persistent symptoms.